Jacobs Levy Equity Management Inc. Sells 329,335 Shares of Personalis, Inc. (NASDAQ:PSNL)

Jacobs Levy Equity Management Inc. cut its holdings in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 44.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 405,670 shares of the company's stock after selling 329,335 shares during the period. Jacobs Levy Equity Management Inc. owned 0.76% of Personalis worth $2,183,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. ARK Investment Management LLC grew its holdings in Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company's stock valued at $38,120,000 after buying an additional 723,637 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company's stock worth $1,237,000 after acquiring an additional 66,128 shares during the last quarter. Walleye Capital LLC bought a new position in Personalis during the third quarter worth $897,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Personalis by 98.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 108,788 shares of the company's stock worth $585,000 after acquiring an additional 53,965 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Personalis by 58.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company's stock valued at $142,000 after purchasing an additional 34,900 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PSNL shares. BTIG Research boosted their price objective on shares of Personalis from $5.50 to $7.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Needham & Company LLC restated a "buy" rating and set a $7.25 price target on shares of Personalis in a research note on Thursday, November 7th. Finally, HC Wainwright raised their price objective on Personalis from $7.50 to $9.00 and gave the stock a "buy" rating in a research report on Monday, August 19th.

Personalis Stock Performance

Shares of NASDAQ:PSNL traded up $0.37 during midday trading on Friday, reaching $4.15. 617,890 shares of the company's stock were exchanged, compared to its average volume of 874,894. The company's 50 day simple moving average is $4.55 and its two-hundred day simple moving average is $3.72. Personalis, Inc. has a 12 month low of $1.12 and a 12 month high of $7.20. The firm has a market capitalization of $293.20 million, a PE ratio of -2.47 and a beta of 1.88.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The business had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same period last year, the company earned ($0.51) EPS. On average, research analysts anticipate that Personalis, Inc. will post -1.41 earnings per share for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.